<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03225924</url>
  </required_header>
  <id_info>
    <org_study_id>ENTO-R-CHOP</org_study_id>
    <nct_id>NCT03225924</nct_id>
  </id_info>
  <brief_title>Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI&gt;=1 Treated by Chemiotherapy</brief_title>
  <official_title>Phase Ib - II Study of Entospletinib (ENTO) in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) Patients With aaIPI&gt;=1 Treated by Rituximab, Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone (R-CHOP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Lymphoma Academic Research Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Lymphoma Academic Research Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the phase Ib of the study is to determine the recommended phase 2&#xD;
      dose (RP2D) for entospletinib (ENTO) in patients treated with R-CHOP.&#xD;
&#xD;
      The primary objective of the phase II is to determine the complete metabolic response (CMR)&#xD;
      rate by the Lugano classification 2014 (Deauville scale 1-3) at the end of treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Stop of drug development&#xD;
  </why_stopped>
  <start_date type="Actual">July 26, 2017</start_date>
  <completion_date type="Actual">October 18, 2019</completion_date>
  <primary_completion_date type="Actual">October 18, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: recommended phase 2 dose</measure>
    <time_frame>6 months</time_frame>
    <description>To determine the recommended phase 2 dose for Entospletinib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Complete Metabolic Response (CMR) rate at the end of treatment</measure>
    <time_frame>168 days</time_frame>
    <description>To determine the CMR rate by the Lugano classification 2014 (Deauville scale 1-3) at the end of treatment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>DLBCL</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Entospletinib + Rituximab + Cyclophosphamide + Doxorubicine + Vincristine + Prednisone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entospletinib</intervention_name>
    <description>200mg or 400mg twice a day for 7 days every 21 cycles - total of 8 cycles</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>ENTO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>cycles of 21 days - 375mg/m²</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Mabthera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>cycles of 21 days - 750 mg/m²</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>cycles of 21 days - 50mg/m²</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>cycles of 21 days - 1.4mg/m²</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>cycles of 21 days - 40mg/m²</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with histologically confirmed de novo DLBCL (CD20 positive) (cf section 20.6&#xD;
             - Appendix 4)&#xD;
&#xD;
          2. Age between 60 and 80 years included, on the day of the informed consent document&#xD;
             signature&#xD;
&#xD;
          3. Age adjusted International Prognosis Index (aaIPI) score ≥ 1&#xD;
&#xD;
          4. No prior treatment for DLBCL. However prephase treatment with 1mg/kg/day prednisone or&#xD;
             equivalent, for a maximum of 14 days, is permitted prior to begin the treatment&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 (0 or 1 only&#xD;
             for phase 1b)&#xD;
&#xD;
          6. Life expectancy of ≥ 90 days (3 months) before starting Entospletinib&#xD;
&#xD;
          7. Signed informed consent&#xD;
&#xD;
          8. At least one bi-dimensionally measurable lesion defined as at least one node or tumor&#xD;
             lesion on CT scan ≥ 1.5 cm&#xD;
&#xD;
          9. fluorodeoxyglucose (FDG) positron emission tomography (PET-CT) performed at baseline&#xD;
             with a FDG positive result&#xD;
&#xD;
         10. Adequate hematologic functions defined as follows (unless secondary to bone marrow&#xD;
             involvement by lymphoma):&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &gt; 1.5 X 10^9 G/l and&#xD;
&#xD;
               -  Platelets count ≥ 75 X 10^9/l without platelet transfusion dependency during the&#xD;
                  last 7 days and&#xD;
&#xD;
               -  Haemoglobin level &gt; 9 g/dl (may receive transfusion)&#xD;
&#xD;
         11. Adequate liver function defined as follows:&#xD;
&#xD;
               -  Total bilirubin &lt;1.5 upper limit of normal (ULN) except for unconjugated&#xD;
                  hyperbilirubinemia of Gilbert's syndrome and&#xD;
&#xD;
               -  Alkaline phosphatase (in absence of bone disease), alanine aminotransferase (ALT)&#xD;
                  and aspartate aminotransferase (AST) &lt; 3 X ULN&#xD;
&#xD;
         12. Adequate renal function as calculated by a creatinine clearance &gt; 40 ml/min by local&#xD;
             institutional formula&#xD;
&#xD;
         13. Patients with prior Hepatitis B must be given antiviral prophylaxis and hepatitis B&#xD;
             virus (HBV) DNA monitored; Patients with prior Hepatitis C are eligible if, hepatitis&#xD;
             C virus (HCV) RNA is undetectable.&#xD;
&#xD;
         14. Left ventricular ejection fraction (LVEF) ≥ 50% of echocardiography or multiple gated&#xD;
             acquisition (MUGA) scan&#xD;
&#xD;
         15. Adequate tissue for central retrospective testing for cell of origin (10-15 slides of&#xD;
             tumor biopsy must be available at baseline)&#xD;
&#xD;
         16. Heterosexually active females of childbearing potential (as defined in the protocol)&#xD;
             must:&#xD;
&#xD;
               -  have a negative serum pregnancy test at baseline and prior to the first study&#xD;
                  drug administration (C1D-4)&#xD;
&#xD;
               -  have practiced at least 1 reliable method of contraception for at least 2 months&#xD;
                  prior to the first study drug administration (C1D-4)&#xD;
&#xD;
               -  agree to utilize highly effective methods of contraception (as defined in the&#xD;
                  protocol) from Cycle 1 Day -4 until 12 months following the last treatment&#xD;
                  administration&#xD;
&#xD;
         17. Heterosexually active males with partners of childbearing potential must agree to use&#xD;
             reliable forms of contraception during treatment and up to 12 months after last&#xD;
             treatment administration&#xD;
&#xD;
         18. Male subjects must agree to avoid sperm donation from Cycle 1 Day -4 until 12 months&#xD;
             following the last treatment administration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Central nervous system or meningeal involvement with DLBCL&#xD;
&#xD;
          2. Contraindication to any drug contained in the chemotherapy regimen&#xD;
&#xD;
          3. Prior treatment with Entospletinib or other spleen tyrosine kinase (SYK ) inhibitor&#xD;
&#xD;
          4. Patients with a prior history of other malignancy, exceptions include:&#xD;
&#xD;
               -  a subject who has been disease-free after curative local treatment (surgical&#xD;
                  resection) for at least 3 years,&#xD;
&#xD;
               -  a subject with a history of a completely resected non-melanoma skin cancer or in&#xD;
                  situ carcinoma with surgical complete excision.&#xD;
&#xD;
          5. Patients taking current therapy with proton pump inhibitors and current therapy with&#xD;
             medicines that are strong Cytochrome P450 3A (CYP3A) or CYP2C9 inducers, or moderate&#xD;
             CYP2C9 inducers.&#xD;
&#xD;
          6. Ongoing active pneumonitis&#xD;
&#xD;
          7. Peripheral sensory or motor neuropathy grade &gt; 1.&#xD;
&#xD;
          8. Major surgery within 4 weeks before first dose of study drug (minor procedures&#xD;
             including transcutaneous biopsy, central line placement are permitted at any time)&#xD;
&#xD;
          9. Inability to take oral medication or malabsorption syndrome or any other uncontrolled&#xD;
             gastrointestinal condition that would impair ability to take entospletinib&#xD;
&#xD;
         10. Significant cardiovascular impairment: congestive heart failure greater than New York&#xD;
             Heart Association (NYHA) Class II, unstable angina, myocardial infarction or stroke&#xD;
             within 6 months of first dose of entospletinib or ventricular arrhythmia&#xD;
&#xD;
         11. Active infection as judged by the investigator&#xD;
&#xD;
         12. Known hypersensitivity to ENTO&#xD;
&#xD;
         13. Congenital immunodeficiency or known HIV (human immunodeficiency virus infection) or&#xD;
             active viral hepatitis B or C&#xD;
&#xD;
         14. Any other major illness that in the investigator's judgement, will substantially&#xD;
             increase the risk associated with the subject's participation in the study&#xD;
&#xD;
         15. Subjects who have undergone a solid organ transplant and stem cell transplant&#xD;
&#xD;
         16. Previous treatment for B cell lymphoma or Richter's transformation&#xD;
&#xD;
         17. Primary Mediastinal B Cell Lymphoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles Salles</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emmanuelle Tchernonog</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julien Depaus</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCL Namur</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Universite Catholique de Louvain Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Joliment</name>
      <address>
        <city>Haine-Saint-Paul</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az Groeninge</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCL Namur</name>
      <address>
        <city>Yvoir</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch de Bourg En Bresse</name>
      <address>
        <city>Bourg-en-Bresse</city>
        <zip>0100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch de Versailles - Hopital Andre Mignot</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Limoges - Hopital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de La Sauvegarde</name>
      <address>
        <city>Lyon</city>
        <zip>69337</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Region Mulhouse Et Sud Alsace</name>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Necker Paris</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Bordeaux</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Annecy Genevois</name>
      <address>
        <city>Pringy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Reims - Hopital Robert Debre</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Rennes - Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch de Roubaix-Hopital Victor Provo</name>
      <address>
        <city>Roubaix</city>
        <zip>59056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iuct Oncopole de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bretonneau- Centre H. Kaplan</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch de Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <zip>59322</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chru de Nancy</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 20, 2017</study_first_submitted>
  <study_first_submitted_qc>July 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>September 1, 2020</last_update_submitted>
  <last_update_submitted_qc>September 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

